Form 4: Tyra Biosciences Insider Stock Transaction

Bhavesh Ashar, Chief Operating Officer of Tyra Biosciences, Inc., reported a transaction involving the acquisition of restricted stock units and stock options.

Summary

• Bhavesh Ashar, Chief Operating Officer of Tyra Biosciences, Inc., acquired 15,013 restricted stock units (RSUs) on May 5, 2026, with a transaction value of $0.
• These RSUs vest over four years, with 1/4 vesting on each anniversary of May 5, 2026, contingent on continued service.
• Ashar was also granted a stock option to purchase 50,295 shares of common stock at an exercise price of $33.93.
• The stock option vests over time, with 25% vesting on May 5, 2027, and the remainder vesting monthly thereafter, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard executive compensation and not a new strategic development or financial performance indicator.

Positives

• Grant of restricted stock units and stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
• The stock option grant at $33.93 suggests a strike price at or above the current market price, implying a belief in future stock appreciation.

Negatives

• The acquisition of RSUs and stock options is part of Ashar's compensation and not an open market purchase, meaning it doesn't directly reflect personal investment conviction based on current market conditions.

Risks

• Vesting of RSUs and stock options is contingent on continued service, meaning a departure from the company before vesting would result in forfeiture.
• The value of the RSUs and stock options is directly tied to the future performance and stock price of Tyra Biosciences, which carries inherent market and company-specific risks.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a forward-looking incentive structure tied to continued employment and the company's future stock performance.

Industry Context

StockSavvy.ai notes that grants of stock options and RSUs are standard practice in the biotechnology sector for executive compensation, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term stock performance, potentially benefiting shareholders if the company's value increases.
• Employees: The structure of RSUs and options may influence employee retention and motivation.
• Management: Bhavesh Ashar's compensation is directly linked to the company's future success through these equity awards.

Next Steps

• Continuous service through vesting dates for RSUs and stock options.
• Potential exercise of stock options upon vesting, subject to market conditions and personal financial planning.

Key Dates

Keywords

Tyra Biosciences, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Bhavesh Ashar, SEC Filing